a6848m
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of September 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
New
Sustainability Committee of the Board
23 September 2021 07:00 BST
AstraZeneca establishes new Sustainability Committee of the
Board
AstraZeneca PLC announced today that the Board has established a
Sustainability Committee. The Committee has been constituted to
monitor the execution of the Company's sustainability strategy, to
oversee the communication of the Company's sustainability
activities with its stakeholders and to provide input to the Board
and other Board Committees on sustainability matters. The terms of
reference of the Committee are available
at www.astrazeneca.com/content/dam/az/Investor_Relations/corporate-governance/AZ_Sustainability_Committee_ToRs.pdf.
The members of the Committee, all of whom are Non-Executive
Directors of the Company, are Nazneen Rahman (Chairman of the
Committee), Sheri McCoy, Andreas Rummelt and Marcus Wallenberg.
These appointments take effect and the Committee will operate from
1 October 2021.
The establishment of a Sustainability Committee is a natural
evolution of the Company's previous governance arrangement of
having a single Board member with responsibility for overseeing
sustainability matters on behalf of the Board.
Further information about sustainability at AstraZeneca is
available at www.astrazeneca.com/sustainability.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
23 September 2021
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|